ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers Signs Deals With Biotechs

by Ann M. Thayer
June 2, 2014 | APPEARED IN VOLUME 92, ISSUE 22

Bristol-Myers Squibb will pay $50 million up front to access CytomX Therapeutics’ Probody technology for up to four cancer targets. BMS will also provide research funding and up to $298 million in milestone payments for each collaboration target. Probodies are monoclonal antibodies that can be selectively activated at the cancer site to spare healthy tissue. In another deal, BMS and Incyte will conduct initial clinical trials on a cancer-fighting combination of BMS’s nivolumab, a PD-1 immune checkpoint inhibitor, and Incyte’s oral indoleamine dioxygenase-1 inhibitor.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment